Dolby Family Ventures
VC Fund
San Francisco, United States
Dolby Family Ventures is an early stage venture firm focused on building great technology companies. They partner with best-in-class innovators and strong investment syndicate partners at the seed stage of a company’s development. Unlike many seed investors, They intend to continue to invest across future rounds in our successful portfoliocompanies.
- Total investments:
- 144
- Last investment:
- Lead investor:
- 8%
Last updated:
For AI agents: llms.txt
Industries Dolby Family Ventures invests in
Stages Dolby Family Ventures invests in
Countries Dolby Family Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $2M–$9.4M
- Series A
- $6.5M–$50M
- Series B
- $10M–$65M
Investment Focus
Industry
- Biotechnology 34 (24%)
- Health Care 22 (15%)
- Software 15 (10%)
- Therapeutics 15 (10%)
- Medical 14 (10%)
Stage
- Series A 47 (33%)
- Seed 32 (22%)
- Series B 26 (18%)
- Series C 9 (6%)
- Funding Round 4 (3%)
Country
- United States 81 (56%)
- Austria 2 (1%)
- Germany 2 (1%)
- Switzerland 2 (1%)
- Israel 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Andrew Krowne
Managing Director
|
Managing Director | Total investments: 5 | Find email | |
David Dolby
CEO
|
CEO | Total investments: 4 | Find email | |
|
Kavan Canekeratne
Associate; Associate
|
Associate; Associate | Total investments: 0 | Find email | |
Pascal Levensohn
Senior Managing Director
|
Senior Managing Director | Total investments: 15 | Find email | |
Reetika Bhardwaj
Principal
|
Principal | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Exciva
|
exciva is a Provider of targeted drug rescue program intended to involve pharmaceutical research and development based in Heidelberg, Germany. The company's program has been formulated for developing symptomatic and disease-modifying treatments, therapies, cures, prophylactics, supplements, formulations and methods of making and using suchcompositions, enabling the healthcare industry to access their program for rescuing and reusing approved drugs for new indications and new uses. | $62.2M / Series B / Jan 20, 2026 | |
Transition Metal Solutions
|
Transition Biomining is a metal ore mining technology company that offers data driven solutions for copper extraction and mining. | $6M / Seed / Jan 15, 2026 | |
MindImmune Therapeutics
|
MindImmune Therapeutics is a pharmaceutical company developing first-in-class drugs that target the immune system to treat diseases of the central nervous system, including Alzheimer’s and Huntington’s disease, pain, and psychiatric disorders. It is increasingly clear that the central nervous system and the immune system are intimately integrated.Consequently, immune system dysfunction is a critical, often causative, factor in brain dysfunction. MindImmune scientists are at the forefront in recognizing the therapeutic opportunities in targeting the immune system to treat brain disease. MindImmune is based in Kingston, RI and is building an affiliation with the George & Anne Ryan Institute for Neuroscience at the University of Rhode Island to leverage the rapidly expanding Rhode Island ecosystem of academic neurosciences resources to advance its drug development programs. | $15.2M / Series A / Nov 24, 2025 | |
Mojo Vision
|
Mojo Vision is a developer of augmented reality products and platforms intended to invent the future of computing. The company has developed a smart contact lens with a built-in display that gives timely information without interrupting the focus and delivers immediate, powerful, and relevant information without the intrusions of today'smobile devices, enabling users to connect with others at a glance, anytime, anywhere handsfree.Mojo Vision was founded in 2015 and headquartered in Saratoga, California. | $75M / Series B / Sep 04, 2025 | |
Sensorium Therapeutics
|
Sensorium Therapeutics is a drug discovery platform that develops novel FDA-approved psychoactive medicines. Founded in 2021, the company is based in Boston, Massachusetts. | $25M / Series A / Aug 29, 2025 | |
Soil Action
|
Soil Action offers AI-enabled real-time soil analysis developed by the Foundational Model for Soil, which allows them to see into the ground, direct agricultural implements, unlock latent crop yield potential, improve plant and food nutrition, and reduce fertilizer waste and its environmental effects. This technology is aimed at enhancing soilmanagement and agricultural productivity. | $5.3M / Seed / Aug 12, 2025 | |
Magnefy
|
Magnefy (previously known as Infinion) is a Stanford spin-out pioneering an edge AI-powered, high-frequency magnetic sensing platform for real-time predictive maintenance of critical power assets like transformers, switchgear, and generators. Our $500 non-invasive IoT solution captures 250× more low-noise, high-frequency data—accurately detectingfailures like partial discharge and higher harmonics weeks to months in advance, at one-tenth the cost of legacy systems. We help mission-critical facilities—data centers, IPPs, utilities, and manufacturers—avoid outages, boost reliability, and maximize power efficiency. | $1.7M / Pre-Seed / Aug 04, 2025 | |
Salvia BioElectronics
|
Salvia is an innovative startup active in the emerging field of bioelectronics. The name Salvia is derived from the Latin word salvere, which means to stay healthy. In addition, the Salvia-plant has been used to treat headaches, pain, and mental disorders over centuries. Salvia's mission is to deliver bioelectronic solutions that restorehealth for people suffering from chronic migraine. Salvia aims to provide drug-free solutions that are effective and inherently side-effect free and make the novel solutions widely accessible. The Salvia team consists of experienced entrepreneurs, engineers and scientists with diverse professional backgrounds and proven track-record throughout the medical device industry (Sapiens, Medtronic, Philips, St Jude, BioSensors International, Kyphon, etc). | $60.1M / Series B / May 27, 2025 | |
Therini Bio
|
Therini Bio is dedicated to the research and development of novel therapeutics for the treatment of neurological diseases. The company's approach is based on novel findings by the Akassoglou lab at Gladstone/UCSF that implicate fibrin as a key driver of neuroinflammation. | $39M / Series A / May 14, 2025 | |
Potato
|
AI research assistant for biology. | $6.6M / Seed / Apr 08, 2025 | |
| See all 144 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Dolby Family Ventures invest in?
Dolby Family Ventures invests primarily in Biotechnology, Health Care and Software startups, most often at Series A and Seed stage. Most of the 144 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Dolby Family Ventures's check size?
Dolby Family Ventures typically joins rounds of $2M–$9.4M at Seed, $6.5M–$50M at Series A and $10M–$65M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Dolby Family Ventures participates in.
How do I contact Dolby Family Ventures?
Public channels for Dolby Family Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Dolby Family Ventures?
The team at Dolby Family Ventures includes Andrew Krowne (Managing Director), David Dolby (CEO) and Kavan Canekeratne (Associate; Associate). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
